NAV

Florbenazine F-18

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Florbenazine F-18
Accession Number
DB14945
Description

Florbenazine F-18 is under investigation in clinical trial NCT01515384 (A Trial of 18F-AV-133 Positron Emission Tomography (PET)).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
3D
Similar Structures
Weight
Average: 364.492
Monoisotopic: 364.239156561
Chemical Formula
C21H32FNO3
Synonyms
  • 18F-AV-133

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
KM31LBX59H
CAS number
956903-29-0
InChI Key
GNKGXQHHUUEYQV-WTHAECTESA-N
InChI
InChI=1S/C21H32FNO3/c1-14(2)9-16-13-23-7-5-15-10-21(26-8-4-6-22)20(25-3)11-17(15)18(23)12-19(16)24/h10-11,14,16,18-19,24H,4-9,12-13H2,1-3H3/t16-,18-,19-/m1/s1/i22-1
IUPAC Name
(2R,3R,11bR)-9-[3-(¹⁸F)fluoropropoxy]-10-methoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-ol
SMILES
COC1=C(OCCC[18F])C=C2CCN3C[C@@H](CC(C)C)[C@H](O)C[C@@H]3C2=C1

References

General References
Not Available
ChemSpider
26338549
ChEMBL
CHEMBL1780010
ZINC
ZINC000100529342

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2, 3CompletedDiagnosticLewy Body Parkinson's Disease / Parkinson's Disease (PD) / Primary Parkinsonism1
1CompletedDiagnosticType 2 Diabetes Mellitus1
1TerminatedDiagnosticType 1 Diabetes Mellitus / Type 2 Diabetes Mellitus1
1, 2CompletedDiagnosticAlzheimer's Disease (AD) / Diffuse Lewy Body Disease / Parkinson's Disease (PD)1
Not AvailableCompletedNot AvailableType 1 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0472 mg/mLALOGPS
logP3.2ALOGPS
logP2.93ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)14.85ChemAxon
pKa (Strongest Basic)8.18ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.93 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity101.86 m3·mol-1ChemAxon
Polarizability42.07 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 08:37 / Updated on June 12, 2020 10:53

Ddi 3